{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:35:21Z","timestamp":1789263321955,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>BE SURE 1-year results demonstrated the superior efficacy of bimekizumab compared with adalimumab with no unexpected safety findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To provide efficacy and safety data over 2 years of bimekizumab treatment compared with adalimumab from BE SURE and the BE BRIGHT open-label extension (OLE) in patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The 56-week double-blinded BE SURE phase III randomized controlled trial randomized patients 1 : 1 : 1 to bimekizumab 320\u2005mg every 4 weeks (Q4W), bimekizumab 320\u2005mg Q4W to week 16 then every 8 weeks (Q8W), or adalimumab 40\u2005mg every 2 weeks to week 24 then bimekizumab 320\u2005mg Q4W. After completing BE SURE, patients could enter the ongoing BE BRIGHT OLE, with possible dosing adjustments based on Psoriasis Area and Severity Index (PASI). The primary outcome in BE BRIGHT was incidence of treatment-emergent adverse events (TEAEs); safety data are reported by study period through week 104. Efficacy data are reported for the intention-to-treat population through week 104 by initial randomization group, with \u2265 90% improvement from baseline PASI (PASI 90) and 100% improvement (PASI 100) as key outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the patients randomized to bimekizumab, 158 were assigned to Q4W, and 161 to Q4W\/Q8W. At week 104, PASI 90 was achieved by 91.2% and 89.7%, and PASI 100 was achieved by 72.3% and 68.1%, for Q4W and Q4W\/Q8W, respectively; comparable to week 16 results. Among the 159 patients randomized to adalimumab, responses rapidly and substantially increased after the week 24 bimekizumab switch; at week 104, 96.9% and 70.2% of patients achieved PASI 90 and PASI 100 respectively. Through weeks 24\u2013104, the three most common TEAEs in any bimekizumab-treated group were nasopharyngitis, oral candidiasis and upper respiratory tract infection. Rates of serious TEAEs were low.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Clinical responses observed through week 16 of BE SURE in patients randomized to bimekizumab were sustained through 104 weeks of treatment, regardless of Q4W or Q8W maintenance dosing. Response rates were also sustained through week 104 in patients who switched from adalimumab to bimekizumab at week 24, and were similar to those observed in the bimekizumab groups. Bimekizumab was well tolerated with no new safety signals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljac021","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T07:10:30Z","timestamp":1673161830000},"page":"22-31","source":"Crossref","is-referenced-by-count":32,"title":["Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"first","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine, University Hospital of L\u00fcbeck , L\u00fcbeck , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"Ron","family":"Vender","sequence":"additional","affiliation":[{"name":"Dermatrials Research Inc. , Hamilton, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno A","family":"de Rie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam University Medical Centres , Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lausanne University Hospital , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Pariser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eastern Virginia Medical School , Norfolk, VA , USA"},{"name":"Virginia Clinical Research, Inc. , Norfolk, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"Yale University , New Haven, CT , USA"},{"name":"Central Connecticut Dermatology Research , Cromwell, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Vanvoorden","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Wang","sequence":"additional","affiliation":[{"name":"UCB Pharma, Raleigh, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Madden","sequence":"additional","affiliation":[{"name":"UCB Pharma, Raleigh, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"de Cuyper","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B","family":"Kimball","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"2023100516254568000_ljac021-B1","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/j.1365-2133.2010.09693.x","article-title":"The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics","volume":"162","author":"Driessen","year":"2010","journal-title":"Br J Dermatol"},{"key":"2023100516254568000_ljac021-B2","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2023100516254568000_ljac021-B3","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1111\/jdv.16568","article-title":"A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)","volume":"34","author":"Seneschal","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100516254568000_ljac021-B4","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023100516254568000_ljac021-B5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"35","key":"2023100516254568000_ljac021-B6","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2023100516254568000_ljac021-B7","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2023100516254568000_ljac021-B8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2040622318772705","article-title":"Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience","volume":"9","author":"Sator","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"2023100516254568000_ljac021-B9","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s40265-015-0503-x","article-title":"Adalimumab: a review in chronic plaque psoriasis","volume":"75","author":"Burness","year":"2015","journal-title":"Drugs"},{"key":"2023100516254568000_ljac021-B10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis","volume":"18","author":"Revicki","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"2023100516254568000_ljac021-B11","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/09546634.2019.1610553","article-title":"Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience","volume":"31","author":"Barker","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2023100516254568000_ljac021-B12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-019-00355-4","article-title":"Adalimumab biosimilars in Europe: an overview of the clinical evidence","volume":"33","author":"Bellinvia","year":"2019","journal-title":"BioDrugs"},{"key":"2023100516254568000_ljac021-B13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40744-020-00259-8","article-title":"Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity","volume":"8","author":"Huizinga","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2023100516254568000_ljac021-B14","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2013 part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100516254568000_ljac021-B15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100516254568000_ljac021-B16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023100516254568000_ljac021-B17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100516254568000_ljac021-B18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1468-3083.2012.04515.x","article-title":"Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study","volume":"27","author":"Papp","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100516254568000_ljac021-B19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50\u2005mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"key":"2023100516254568000_ljac021-B20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023100516254568000_ljac021-B21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Eng J Med"},{"key":"2023100516254568000_ljac021-B22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023100516254568000_ljac021-B23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023100516254568000_ljac021-B24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023100516254568000_ljac021-B25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther (Heidelb"},{"key":"2023100516254568000_ljac021-B26","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"issue":"177","key":"2023100516254568000_ljac021-B27","article-title":"Targeting inflammation to prevent cardiovascular disease in chronic rheumatic diseases: myth or reality?","volume":"5","author":"Bartoloni","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"2023100516254568000_ljac021-B28","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.jid.2021.02.743","article-title":"New frontiers in psoriatic disease research, part II: comorbidities and targeted therapies","volume":"141","author":"Yan","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2023100516254568000_ljac021-B29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023100516254568000_ljac021-B30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000113150","article-title":"Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis","volume":"216","author":"Revicki","year":"2008","journal-title":"Dermatology"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac021\/48522752\/ljac021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/1\/22\/51888185\/ljac021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/1\/22\/51888185\/ljac021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T16:26:38Z","timestamp":1696523198000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/1\/22\/6773096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,21]]},"published-print":{"date-parts":[[2023,1,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac021","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1]]},"published":{"date-parts":[[2023,1]]}}}